USP Acquires Pharmatech Associates

United States Pharmacopeia (USP), the scientific nonprofit organization, has acquired Pharmatech Associates, Inc., a regulatory consulting service, to assist manufacturers to meet global quality standards, USP reported on July 7, 2021.

The acquisition of Pharmatech expands USP’s capabilities to strengthen the supply chain of quality medicines and builds on work with regulators and manufacturers to address industry problems. Pharmatech’s services include helping drug manufacturers meet global regulatory requirements, scale up manufacturing, manage quality control, and remediate quality problems.

“The drug recalls we’ve seen in recent years and the supply chain challenges underscored by the COVID-19 pandemic have raised concerns about ongoing quality and safety issues,” said Ronald T. Piervincenzi, USP’s chief executive officer in a press announcement. “This announcement positions us to continue to strengthen the supply chain and extend our many years of collaborating with global regulators and manufacturers to ensure the quality of medicines as we have done with our donor-funded work and ingredient verification services for API and excipients.”

“We are pleased to share with USP the goal of helping manufacturers to bring safe and effective treatments to patients who need them. We bring a high standard of service to our clients, grounded in scientific excellence, and designed to meet the future compliance, quality, and business performance needs of the global healthcare industry.” Bikash Chatterjee, CEO and chairman, Pharmatech Associates in the press announcement.

Pharmatech Associates and its employees will operate independent of USP, the organization reports.

Source: United States Pharmacopeia